Document is current
Any future updates will be listed below
-
Authors
McFaline-Figueroa, J. Ricardo https://orcid.org/0000-0002-6670-1841
Sun, Lu https://orcid.org/0000-0002-6592-1156
Youssef, Gilbert C.
Huang, Raymond
Li, Gang
Kim, Jiyoon
Lee, Eudocia Q.
Nayak, Lakshmi
Chukwueke, Ugonma
Beroukhim, Rameen https://orcid.org/0000-0001-6303-3609
Batchelor, Tracy T.
Chiocca, E. Antonio https://orcid.org/0000-0001-5183-1670
Everson, Richard G. https://orcid.org/0000-0003-2809-3061
Doherty, Lisa
Stefanik, Jennifer
Partridge, Kathryn
Spearman, Amanda
Myers, Alexa
Westergaard, Catharina
Russ, Alyssa https://orcid.org/0000-0002-6353-139X
Lavallee, Maria
Smokovich, Anna
LaForest-Roys, Corey
Garcia Fox, Rachel
McCluskey, Christine
Bi, Wenya Linda
Arnaout, Omar
Peruzzi, PierPaolo https://orcid.org/0000-0001-5034-2963
Cosgrove, G. Rees
Ligon, Keith L. https://orcid.org/0000-0002-7733-600X
Arrillaga-Romany, Isabel
Clarke, Jennifer L. https://orcid.org/0000-0002-8054-7342
Reardon, David A. https://orcid.org/0000-0001-6674-0157
Cloughesy, Timothy F. https://orcid.org/0000-0002-8656-7483
Prins, Robert M. https://orcid.org/0000-0002-6282-6583
Wen, Patrick Y. https://orcid.org/0000-0002-0774-7700
-
Funding
Funding for this research was provided by:
Ben and Catherine Ivy Foundation
- License Information
-
More Information
Article History
Received: 9 August 2024
Accepted: 29 October 2024
First Online: 30 December 2024
Competing interests
: The authors declare the following competing interests: P.P. is the founder and owns equity of Ternalys Therapeutics, inventor of US Patent 11946064 related to non-coding RNA technology. T.F.C. is cofounder, major stock holder, consultant and board member of Katmai Pharmaceuticals, holds stock for Erasca, member of the board and paid consultant for the 501c3 Global Coalition for Adaptive Research, holds stock in Chimerix and receives milestone payments and possible future royalties, member of the scientific advisory board for Break Through Cancer, member of the scientific advisory board for Cure Brain Cancer Foundation, has provided paid consulting services to Third Rock, Symbio, Mundipharma, Tango BlueRock, Vida Ventures, Lista Therapeutics, Stemline, Novartis, Roche, Sonalasense, Sagimet, Clinical Care Options, Ideology Health, Servier, Jubilant, Immvira, Gan & Lee, BrainStorm, Katmai, Sapience, Inovio, Vigeo Therapeutics, DNATrix, Tyme, SDP, Kintara, Bayer, Merck, Boehinger Ingelheim, VBL, Amgen, Kiyatec, Bayer, Abbvie, VBI, Deciphera, VBL, Agios, Novocure, Medscape and has contracts with UCLA for the Brain Tumor Program with Servier, Roche, VBI, Merck, Novartis, BMS, In8bio. The Regents of the University of California (T.F.C. employer) has licensed intellectual property co-invented by TFC to Katmai Pharmaceuticals. P.W. receives research support from Astra Zeneca, Black Diamond, Bristol Meyers Squibb, Chimerix, Eli Lily, Erasca, Global Coalition For Adaptive Research, Kazia, MediciNova, Merck, Novartis, Quadriga, Servier, VBI Vaccines; is a Advisory Board/Consultant to Anheart, Astra Zeneca, Black Diamond, Celularity, Day One Bio, Genenta, Glaxo Smith Kline, Kintara, Merck, Mundipharma, Novartis, Novocure, Sapience, Servier, Symbio, Tango, Telix. R.B. receives funding from Novartis; is a consultant for Scorpion Therapeutics. R.P. receives research support from Merck. The remaining authors declare no competing interests.
